James Healy
CIK: 0001245624
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (24 total)
- Oct 28, 2026RAPP
Rapport Therapeutics, Inc.
Purchase(P)Indirect952.4K shares at avg. $21.00$20.0M - Oct 28, 2026RAPP
Rapport Therapeutics, Inc.
Purchase(P)Indirect6.4K shares at avg. $21.00$134K - Oct 28, 2026RAPP
Rapport Therapeutics, Inc.
Purchase(P)Indirect3.8K shares at avg. $21.00$79K - Oct 28, 2026RAPP
Rapport Therapeutics, Inc.
Purchase(P)Indirect6.9K shares at avg. $21.00$146K - Jun 10, 2026BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
22K shares- - Jun 10, 2026RAPP
Rapport Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
15.2K shares- - May 4, 2026SPTX
Seaport Therapeutics, Inc.
Conversion(C)Indirect804.4K shares- - May 4, 2026SPTX
Seaport Therapeutics, Inc.
Conversion(C)Indirect1.9M shares- - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Tender Offer(U)Indirect2.2M shares at avg. $8.60$18.9M - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Tender Offer(U)Direct31.6K shares at avg. $8.60$272K - Sep 16, 2025YMAB
Y-mAbs Therapeutics, Inc.
Disposition(D)Direct25.1K shares- - Jun 30, 2025YMAB
Y-mAbs Therapeutics, Inc.
Award(A)Direct25.1K shares- - Jun 17, 2025RAPP
Rapport Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
21.9K shares- - Jun 5, 2025BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
22K shares- - Apr 25, 2025NTRA
Natera, Inc.
Award(A)Direct142 shares- - Jan 31, 2025NTRA
Natera, Inc.
Award(A)Direct114 shares- - Oct 25, 2024NTRA
Natera, Inc.
Award(A)Direct153 shares- - Sep 27, 2024BIOA
BioAge Labs, Inc.
Conversion(C)Indirect1.6M shares- - Sep 27, 2024BIOA
BioAge Labs, Inc.
Purchase(P)Indirect588.9K shares at avg. $18.00$10.6M - Sep 27, 2024BIOA
BioAge Labs, Inc.
Purchase(P)Indirect11.1K shares at avg. $18.00$200K - Sep 27, 2024BIOA
BioAge Labs, Inc.
Purchase(P)Indirect18.4K shares at avg. $18.00$330K - Sep 27, 2024BIOA
BioAge Labs, Inc.
Purchase(P)Indirect21.8K shares at avg. $18.00$393K - Sep 27, 2024BIOA
BioAge Labs, Inc.
Purchase(P)Indirect26.5K shares at avg. $18.00$477K - Sep 25, 2024BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
15K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 28, 2026 |  RAPP Rapport Therapeutics, Inc. | Purchase(P) | 952,380 | $21.00 | $19,999,980 | Indirect |
| Oct 28, 2026 | RAPP Rapport Therapeutics, Inc. | Purchase(P) | 6,395 | $21.00 | $134,295 | Indirect |
| Oct 28, 2026 | RAPP Rapport Therapeutics, Inc. | Purchase(P) | 3,772 | $21.00 | $79,212 | Indirect |
| Oct 28, 2026 | RAPP Rapport Therapeutics, Inc. | Purchase(P) | 6,933 | $21.00 | $145,593 | Indirect |
| Jun 10, 2026 |  BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| Jun 10, 2026 | RAPP Rapport Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 15,200 | - | - | Direct |
| May 4, 2026 |  SPTX Seaport Therapeutics, Inc. | Conversion(C) | 804,379 | - | $0 | Indirect |
| May 4, 2026 | SPTX Seaport Therapeutics, Inc. | Conversion(C) | 1,927,159 | - | $0 | Indirect |
| Sep 16, 2025 |  YMAB Y-mAbs Therapeutics, Inc. | Tender Offer(U) | 2,194,278 | $8.60 | $18,870,791 | Indirect |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Tender Offer(U) | 31,603 | $8.60 | $271,786 | Direct |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Disposition(D) | 25,080 | - | - | Direct |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | Award(A) | 25,080 | - | - | Direct |
| Jun 17, 2025 | RAPP Rapport Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 21,850 | - | - | Direct |
| Jun 5, 2025 | BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| Apr 25, 2025 |  NTRA Natera, Inc. | Award(A) | 142 | - | - | Direct |
| Jan 31, 2025 | NTRA Natera, Inc. | Award(A) | 114 | - | - | Direct |
| Oct 25, 2024 | NTRA Natera, Inc. | Award(A) | 153 | - | $0 | Direct |
| Sep 27, 2024 | BIOA BioAge Labs, Inc. | Conversion(C) | 1,638,236 | - | $0 | Indirect |
| Sep 27, 2024 | BIOA BioAge Labs, Inc. | Purchase(P) | 588,888 | $18.00 | $10,599,984 | Indirect |
| Sep 27, 2024 | BIOA BioAge Labs, Inc. | Purchase(P) | 11,113 | $18.00 | $200,034 | Indirect |
| Sep 27, 2024 | BIOA BioAge Labs, Inc. | Purchase(P) | 18,353 | $18.00 | $330,354 | Indirect |
| Sep 27, 2024 | BIOA BioAge Labs, Inc. | Purchase(P) | 21,814 | $18.00 | $392,652 | Indirect |
| Sep 27, 2024 | BIOA BioAge Labs, Inc. | Purchase(P) | 26,497 | $18.00 | $476,946 | Indirect |
| Sep 25, 2024 | BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 15,000 | - | - | Direct |
1-24 of 24 transactions
About HEALY JAMES
HEALY JAMES (SEC CIK 0001245624) files insider reports with the SEC as Director of Rapport Therapeutics, Inc. (RAPP), Director of BioAge Labs, Inc. (BIOA) and Director of Seaport Therapeutics, Inc. (SPTX). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 13 ownership filings by HEALY JAMES (1 Form 3, 12 Form 4), filed between Sep 25, 2024 and Oct 30, 2026. Those filings report 24 transactions, from Sep 25, 2024 to Oct 28, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on HEALY JAMES's filings is in MENLO PARK, CA.
Recent filings by HEALY JAMES
- Oct 28, 2026: Open-market purchases of RAPP shares (4 lines, Form 4, code P).
- Jun 10, 2026: Grant or award of BIOA derivative securities (Form 4, code A).
- Jun 10, 2026: Grant or award of RAPP derivative securities (Form 4, code A).
- May 4, 2026: Conversions of SPTX shares (2 lines, Form 4, code C).
- Sep 16, 2025: Tender of shares transactions of YMAB shares (2 lines, Form 4, code U).
Other insiders filing for Rapport Therapeutics, Inc. (RAPP)
- Ceesay Abraham, Chief Executive Officer
- Sanchez Ramiro, Director
- Silva Paul M, Director
- Young Wendy B., Director
- PAUL STEVEN M, Director
- MARAGANORE JOHN, Director